AAO 2019 Retina Street Team: J. Fernando Arevalo, MD, FACS

Article

J. Fernando Arevalo, MD, FACS, shares findings from his presentation on using brolucizumab to treat neovascular age-related macular degeneration (AMD), and whether the novel therapy is better than current treatment, at the 2019 annual meeting of the American Academy of Ophthalmology in San Francisco.

Day 3 of the 2019 annual meeting of the American Academy of Ophthalmology features Fernando Arevalo, MD, FACS, as he shares findings from his presentation on using brolucizumab to treat neovascular age-related macular degeneration (AMD), and whether the novel therapy is better than current treatment. 

Read and watch more AAO 2019 Retina Street Team coverage here

Recent Videos
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
CIME 2024: Neda Shamie, MD, reports on a morning session packed with refractive surgery options, retina, glaucoma, and a 'mite-y' Demodex discussion
Highlights from the 18th Annual Controversies in Modern Eye Care Symposium: Arjan Hura, MD, on Refractive Surgery, Retina Care, and Record Attendance
© 2024 MJH Life Sciences

All rights reserved.